
|Videos|July 6, 2023
Adjuvant Ribociclib With Endocrine Therapy in HR+ Breast Cancer: The NATALEE Trial
Expert oncologist Stephanie Graff, MD, FACP, joins the Oncology Brothers to review data from the NATALEE trial and consider the role of adjuvant ribociclib in patients with HR+ breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5











































